This review evaluates recently published data on clinical effects of vitamin D supplementation, focusing on randomized, placebo-controlled trials and nontraditional actions on the cardiovascular and immune systems.
INTRODUCTION
Vitamin D is unique among vitamins: it can be acquired through diet, typically from fortified foods or supplements, or generated through cutaneous synthesis following sunlight exposure. A combination of ultraviolet B radiation (UVB) and heat catalyzes conversion of 7-dehydrocholesterol to D 3 (cholecalciferol). D 3 is relatively inactive without further metabolism. The largely unregulated hydroxylation at the 25th position, predominantly in the liver, yields 25-hydroxyvitamin D [25(OH)D]. With its long half-life, 25(OH)D is the most stable and widely used measure of vitamin D status, despite having relatively weak affinity for the vitamin D receptor. The CYP27B1 enzyme (1a-hydroxylase), primarily located in the kidney, converts 25(OH)D to the active vitamin, 1,25-dihydroxyvitamin D (1,25(OH) 2 D).
Renal CYP27B1 activity declines along with glomerular filtration rate (GFR) in advancing chronic kidney disease (CKD). Circulating 1,25(OH) 2 D levels consequently decrease, resulting in reduced absorption of intestinal calcium, hypocalcemia and secondary hyperparathyroidism. Replacement of active vitamin D with calcitriol or one of its analogues has thus become standard therapy in CKD, aimed at normalizing serum calcium and mitigating bone disease caused by secondary hyperparathyroidism.
Several observational and mechanistic studies have suggested that vitamin D's actions may be more broad reaching, and more significant, than originally appreciated. Most tissues in the body express vitamin D receptors [1] . In 2003, Teng et al. [2] found that patients with end-stage renal disease (ESRD) on hemodialysis who received paricalcitol had a more favorable survival profile when contrasted with their calcitriol-treated counterparts. A follow-up study showed similar benefit in patients who received any form of active vitamin D vs. nonsupplemented patients [3] . Although numerous studies have echoed these findings, these have largely been retrospective and observational and thus prone to residual confounding effects [4] [5] [6] [7] [8] [9] .
Animal data on vitamin D has been encouraging. Further investigation into potential beneficial effects on both cardiac function and immunity is particularly relevant as cardiovascular and infectious disease represent the leading causes of morbidity and mortality in ESRD. However, the dearth of prospective interventional studies has tempered initial enthusiasm for vitamin D supplementation. A recent Institute of Medicine report emphasized that data supporting the widespread use of vitamin D for disease prevention and treatment is scant. One high-profile trial aimed at reducing falls and fractures with high dose vitamin D found that treatment in fact increased the risk [10] . Now, new interventional studies are emerging, both in the general and CKD populations.
CLINICAL TRIALS IN THE GENERAL POPULATION
Several recent studies have attempted to establish whether vitamin D supplementation has definite effects on cardiovascular diseases (CVD). In a clinical trial of 305 postmenopausal women, researchers randomized patients to one of two arms of cholecalciferol (400 or 1000 IU per day) or matching placebo for 1 year and examined markers of cardiovascular risk including lipids, apolipoproteins, measures of insulin resistance, inflammatory biomarkers, and blood pressure [11 & ]. Despite the broad range of markers, only small, clinically insignificant differences in apo B100 were detected. Interestingly, significant seasonal variation of blood pressure by 6.6 mmHg (lower in summer) was observed across all arms. Seasonal variation in 25(OH)D levels did not explain these findings, suggesting that season itself may have confounded interpretation of previous data linking vitamin D and blood pressure. Critics might point out that the vitamin D dosage was relatively low: the mean 25(OH)D in the high-dose group reached only 30.4 ng/ml after 12 months of treatment, barely clearing the 30 ng/ml threshold many use to define sufficiency. One could also speculate that the relatively healthy population in this trial had little room to improve. Indeed, many have argued that early trials should focus on high-risk populations to maximize the chance of observing a benefit.
A second trial included 114 ambulatory women with intermediate 25(OH)D levels (10-60 ng/ml) treated with cholecalciferol (2500 IU) and evaluated the changes in vascular function using flowmediated vasodilatation (FMD, a measure of endothelial function), carotid-femoral pulse-wave velocity, and aortic augmentation (measures of arterial stiffness), all of which are predictors of cardiovascular risk [12] . 25(OH)D levels below 30 ng/ml were associated with higher BMI, blood pressure, C-reactive protein (CRP), and FMD. Treatment with cholecalciferol resulted in a 16 ng/ml increase in 25(OH)D, but no difference in any of the outcomes measures was observed between arms. Supplementation effect did not depend on baseline levels, nor was there any observed change in blood pressure. This study reinforces the possibility that previously reported benefits associated with higher 25(OH)D levels from observational studies may have been misinterpreted. Rather than 25(OH)D levels per se, other factors that correlate with both 25(OH)D levels and outcomes may be the key mediators.
Not all interventional trials have been negative. Investigators from Denmark randomized 130 hypertensive patients to 3000 IU of cholecalciferol vs. daily placebo for 20 weeks, and evaluated ambulatory blood pressure and arterial stiffness as measures of cardiovascular health [13 & ]. Unlike prior longterm studies, this focused trial limited vitamin D repletion to winter (October-March). There was a nonsignificant decrease in 24-h blood pressure in the cholecalciferol arm. However, restricting the analysis to individuals with baseline levels of 25(OH)D less than 32 ng/ml, the blood pressure reductions were significant (4 mmHg systolic and 3 mmHg diastolic). Measurement of central SBP by applanation tonometry revealed significant reductions in the cholecalciferol arm by 5 mmHg. Although predictable changes in 25(OH)D and parathyroid hormone (PTH) were observed, changes in renin, angiotensin, and aldosterone were not
KEY POINTS
Initial randomized trials of vitamin D are now emerging, but generally have failed to demonstrate broadly applicable health benefits beyond known effects on bone disease.
Widespread use of vitamin D for nontraditional indications is not supported by current data.
Important large-scale randomized trials are now underway and will yield valuable additional information in years to come. evident. Measures of arterial stiffness were also unchanged. Nonetheless, the study raised the possibility that targeting high-risk individuals may be necessary to observe meaningful clinical changes.
Enhancing immunity, particularly in the CKD population, represents another relevant and promising target for vitamin D therapy that experimental evidence supports. Monocytes and macrophages carry their own inducible 1a-hydroxylase, and vitamin D supplementation appears to boost production of cathelicidin, an antimicrobial peptide with broad-ranging antibacterial properties [14, 15] . Despite encouraging observational data and clear biological rationale, recent interventional studies have been less encouraging.
One study of 322 obese individuals who received either 40 000 or 20 000 IU of cholecalciferol weekly or placebo over a year found no association between 25(OH)D and inflammatory markers such as IL-6 and TNF-a [16] . Even after combining the low and high-dose cholecalciferol groups, no effect of on IL-6 was discovered. The one significant difference between groups was an increased CRP level compared with placebo. Similarly, in the Vitamin D and Acute Respiratory Infection Study (VIDARIS) in New Zealand, high-dose monthly cholecalciferol therapy failed to prevent the development of upper respirator tract infections, or affect missed work days, duration of symptoms, or severity of illness [17 && ]. Instead of focusing on a low-risk healthy population, one trial studied infants less than 1 year old (n ¼ 3046) in Afghanistan, a country with the third highest mortality rate for young children and nearuniversal vitamin D deficiency [18 && ]. Infants were randomized to either 100 000 IU cholecalciferol three times per year or matching placebo. Following intervention, radiographically confirmed first pneumonias were similar in both arms. Further analysis led to some concerning findings, including a higher death rate in the vitamin D arm (4.2 per 1000 vs. 3.4 in the placebo arm), though this difference was neither statistically significant nor a primary outcome. Additionally, children in the vitamin D group had a statistically significant increase in repeat episodes of radiographically confirmed pneumonia [hazard ratio (HR) 1.69; P ¼ <0.0001]. When nonconfirmed pneumonias were also included, the risk was diminished (HR 1.06) but remained statistically significant (P ¼ 0.04).
Insofar as findings in CVD and infections may depend on the population and outcomes studied, heterogeneity has also been observed in outcomes trials. In contrast to the above negative studies, a double-blinded trial of 247 Mongolian children was promising [19 & ]. Children were randomized to daily doses of unfortified or fortified milk (300 IU of cholecalciferol) during the winter. Median baseline 25(OH)D level was profoundly low at 7 ng/ml. The rate of the primary outcome (acute respiratory infection) was halved in the group receiving vitamin D [rate ratio of 0.52 (95% confidence interval: 0.31-0.89)], with no differential effect based on baseline 25(OH)D level. Although the median 25(OH)D level at study completion was considerably higher in the intervention arm, it remained low at 19 ng/ml. This raises the question as to whether population selection plays a role. Another group randomized 95 patients being treated for pulmonary tuberculosis to cholecalciferol (four doses of 100 000 IU) vs. placebo, and found that treatment with vitamin D was associated with faster smear conversion and normalization of white cell counts [20] . Although vitamin D may not be a universal panacea for infectious disease, some signals suggest a potentially important role in specific circumstances and populations.
CLINICAL TRIALS IN CHRONIC KIDNEY DISEASE
Although interventional studies of vitamin D in CKD are scarcer than those in the general population, recent trials have emerged that shed light on potential effects in this vulnerable group. In one trial, 46 patients with stage 2-3 CKD were randomized to high dose cholecalciferol (50 000 IU weekly for 12 weeks, then every other week) or placebo for one year while tracking several cytokines including tumor necrosis factor, IL-6, monocyte chemoattractant protein-1 (MCP-1), interferon-g-induced protein-10 and neutrophil gelatinase associated lipocalin at baseline, 12 weeks and 1 year [21] . MCP-1 was correlated with baseline 25(OH)D levels and decreased 18% by 12 weeks in the intervention arm. The decrease in MCP-1 correlated with the increase in 25(OH)D during this timeframe. Despite these intriguing results, the reduction in MCP-1 did not persist at 1 year. Similarly PTH levels decreased after 12 weeks, but did not remain significantly reduced at 1 year [22] . This lack of persistence could be due to a decline in 25(OH)D levels despite continued treatment or due to other compensatory changes with ongoing exposure to supplementation (e.g. changes in vitamin D metabolism). Another study randomized 52 patients with CKD (half on chronic hemodialysis) to either 40 000 IU cholecalciferol or placebo weekly for 8 weeks [23] . Although 25(OH)D levels rose in treated patients, 1,25(OH) 2 D levels did not increase in the dialysis patients, likely reflecting the loss of 1a-hydroxylase activity that coincides with falling GFR.
Data regarding comparison of different nutritional vitamin D repletion regimens are scarce. The Dialysis Infection and Vitamin D In New England study (DIVINE; NCT00892099) is randomizing 120 incident hemodialysis patients to one of two ergocalciferol arms (50 000 IU weekly or 50 000 IU monthly) or to placebo over 12 weeks and following the response in serum 25(OH)D levels. Secondary outcomes include hospitalizations, changes in cytokines and immunologically active proteins such as cathelicidin.
Given that conversion of 25(OH)D to 1,25(OH) 2 D is impaired in CKD, several trials have studied calcitriol (or its analogs). The VITAL trial found that addition of 2 mg per day paricalcitol to an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker reduced albuminuria in patients with diabetic nephropathy [24] . Two more recent studies have added support to this model of vitamin D action. In one Chinese study, 50 patients with IgA nephropathy and urinary protein excretion more than 0.8 g per day were randomly assigned to either 0.5 mg calcitriol twice weekly or no calcitriol for 48 weeks [25 & ]. All patients had received a reninangiotensin system (RAS) inhibitor for at least 3 months. Protein excretion increased 21% in the control group and decreased 19% in the calcitriol group. Reduction in proteinuria of at least 15% was achieved in 29% of controls vs. 65% in the intervention arm. An open-label study evaluated paricalcitol for proteinuria in 48 patients with at least 0.5 g per day of urinary protein despite anti-RAS therapy after the addition of 1 mg per day of oral paricalcitol for 6 months [26] . Mean 24-h urinary protein measurements were halved, falling from 1.23 to 0.61 g. Three months after stopping paricalcitol, urinary protein returned to pretreatment values. Collectively, these data support a role for active vitamin D analogs in the control of proteinuria.
Not all studies of active vitamin D agents have demonstrated consistent beneficial effects in the CKD population. The multinational PRIMO trial (NCT00497146) evaluated the effect of 2 mg per day paricalcitol on left ventricular hypertrophy (LVH) in 227 patients with Stage 3b and 4 CKD [27 && ]. Patients had mild-to-moderate LVH on echocardiogram at baseline. After 48 weeks of treatment, no difference in left ventricular mass index (primary outcome) or in echocardiographic measurements of diastolic function were detected. However, there was an attenuated rise of B-type natriuretic peptide (BNP) and a lower number of cardiovascular hospitalizations in the paricalcitol group compared with placebo. A posthoc analysis demonstrated that paricalcitol reduced the left atrial volume index compared with placebo [28 & ]. The atrial reverse remodeling correlated with the changes in BNP. Future studies will need to focus on a population at high-risk for hospitalization, such as patients with advanced heart failure. Another small crossover trial in 22 patients with borderline fasting glucose evaluated glucose tolerance, insulin sensitivity, and insulin responsiveness and found no effect of paricalcitol on these measures. However, 1,25(OH) 2 D and 25(OH)D were decreased, while FGF-23 and 24,25(OH) 2 D, an inactive metabolite of vitamin D, were increased [29] . These findings raise the question of whether active vitamin D analogs might have deleterious effects on vitamin D metabolism while increasing FGF-23, a hormone that has been linked to increased mortality in ESRD [29] .
FUTURE DIRECTIONS
Despite the wealth of new information that has emerged, additional trials of both nutritional vitamin D and active vitamin D analogs are still needed. Fortunately, several large trials with a range of outcomes are now underway (Table 1 ). In addition, new frontiers in vitamin D biology are emerging. Recent data from our group suggests that traditional measures of vitamin D status may need to be revisited to account for levels of vitamin D binding protein (VDBP) and albumin, both of which can bind circulating vitamin D. In one model, unbound vitamin D and vitamin D bound relatively weakly to albumin (collectively termed 'bioavailable vitamin D') is free to bind to its receptor, while VDBP-bound is relatively inactive. In healthy young individuals bioavailable 25(OH)D, but not total 25(OH)D levels, correlated with bone density [30] . Similarly, only bioavailable 25(OH)D was associated with serum calcium and PTH in dialysis patients [31] . Future studies will need to validate these findings in other populations. In addition to new assays, new treatments are also emerging. Inhibitors of 24-hydroxylase, the enzyme that catabolizes both 25(OH)D and 1,25(OH) 2 D, may prove useful adjuncts to current therapies [32] .
CONCLUSION
After years of observational studies linking vitamin D to improved outcomes, the results of randomized trials of vitamin D supplementation are finally emerging in the literature and point to decidedly mixed results. Although select high-risk populations with specific disorders may benefit from vitamin D supplementation, broad effects on CVD, immunity, and other nontraditional actions are not supported by current data. Large-scale randomized trials, currently underway, will provide important guidance for treatment practices. In the interim, no established justification exists for the use of nutritional vitamin D analogs in dialysis patients or for using any form of vitamin D for actions outside of mineral metabolism. A prominent exception relevant to patients with CKD may be to control proteinuria, in which several trials have demonstrated a beneficial effect. Trials that target specific populations will likely have the greatest likelihood of demonstrating tangible effects.
